It appears no script is enabled within your browser. Please enable JavaScript to use this site.
Skip header and navigation
Home
View Selections:
0
Items
Help
Print
Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
https://arctichealth.org/en/permalink/ahliterature150689
Source
Curr Med Res Opin. 2009 Jul;25(7):1631-2; author reply 1632-3
Publication Type
Article
Date
Jul-2009
More detail
Author
Joan L Robinson
Source
Curr Med Res Opin. 2009 Jul;25(7):1631-2; author reply 1632-3
Date
Jul-2009
Language
English
Publication Type
Article
Keywords
Antibodies, Monoclonal - economics - therapeutic use
Antibodies, Monoclonal, Humanized
Canada
Cohort Studies
Cost-Benefit Analysis
Gestational Age
Humans
Infant, Newborn
Infant, Premature - physiology
Respiratory Syncytial Virus Infections - congenital - diagnosis - economics - prevention & control
Respiratory Syncytial Virus Vaccines - economics - therapeutic use
PubMed ID
19480611
View in PubMed
Less detail
Permalink